TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17846293
Drug: i.v. low
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. low dose nesiritide (0.005 microg/Kg/min for 24 hours)
Study: 15118189
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (vitamin E, 500 mg/d; vitamin C, 1 g/d; beta-carotene, 30 mg/d)
Study: 11697418
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg retinol equivalent (RE) with childhood immunization
Study: 11697418
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg retinol equivalent (RE) with childhood immunization
Study: 22882543
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 µg twice a day, n = 30)
Study: 22882543
Drug: Fluticasone (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (125 µg twice a day, n = 10)
Study: 20729742
Drug: pegylated interferon‐α‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegylated interferon‐α‐2a (180 μg/week) and ribavirin (1000‐1200 mg/day) for 48 weeks
Study: 12540501
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of 4‐HPR/day for 5 years
Study: 10876750
Drug: Continuous irrigation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous irrigation with 40 micrograms/ml epirubicin solution for 20 hours after surgery
Study: 10876750
Drug: Continuous irrigation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous irrigation with 40 micrograms/ml epirubicin solution for 20 hours after surgery (for solitary tumors)
Study: 2942293
Drug: Kangbao Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangbao Solution
Study: 22127619
Drug: Standard prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prescription instructions (usual care)
Study: 18194120
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (steroid-free regimen): tacrolimus, mycophenolate mofetil, basiliximab induction, and steroids only for 3 days
Study: 18194120
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (steroid maintenance): tacrolimus, mycophenolate mofetil, basiliximab induction, and steroid maintenance
Study: 12133094
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTF) 2.5 ml (15‐20 microg.kg(‐1))
Study: 12133094
Drug: Midazolam syrup
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam syrup (0.5 mg.kg(‐1))
Study: 2181941
Drug: Protocol I
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol I (5-FU 270-300 mg/m2 iv from day 1 to day 5 and ADM 25 mg/m2 iv on day 5)
Study: 2181941
Drug: Protocol II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol II (5-FU, ADM plus CDDP 70 mg/m2 iv on day 1)
Study: 31389672
Drug: Placebo lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lotion for 8 weeks
Study: 9031450
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) 150 anti‐Xa units per kg body weight, administered subcutaneously every 12 h for 7 days, initiated prior to streptokinase (SK)
Study: 9031450
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) 100 anti‐Xa units per kg body weight, administered subcutaneously after dose reduction
Study: 9031450
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) 12,500 i.u. subcutaneously every 12 h for 7 days, initiated 4 h after start of SK infusion
Study: 2104626
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (50 mg/week)
Study: 2104626
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (100 mg/week)
Study: 8132379
Drug: Control (sesame
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sesame oil, 1 ml/week)
Study: 2948735
Drug: t‐PA (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: t‐PA (1.25 mg/kg iv over 3 hrs)
Study: 19699531
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) 1.25 mg injection 1 week before surgery
Study: 16461054
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid (1.8 g ecosapentaenoic acid and 1.2 g docosahexaenoic acid)
Study: 15266193
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (mean serum level 0.99 mEq/L)
Study: 2610663
Drug: Alcohol (0.85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.85 g/kg)
Study: 31688306
Drug: Herbal preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal preparation (myrrh, chamomile flowers, coffee charcoal)
Study: 21732807
Drug: Aquatic exercise
Normalized name: Mentha aquatica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic exercise programme (14 weeks, 40 minutes per session, twice per week)
Study: 14983492
Drug: Screening for
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening for prostate carcinoma with systematic sextant needle biopsy for men with elevated PSA levels and/or positive findings on digital rectal examination or transrectal ultrasound.
Study: 14983492
Drug: Curative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curative treatment offered to patients diagnosed with PAC.
Study: 9203228
Drug: Idazoxan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan (100 micrograms/mg)
Study: 9203228
Drug: Idazoxan (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan (200 micrograms/mg)
Study: 7951859
Drug: Conservative medical
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative medical treatment without EIS
Study: 7370145
Drug: Meptazinol 75
Normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol 75 mg
Study: 3277876
Drug: Self-administered intramuscular
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered intramuscular analgesia
Study: 21443301
Drug: Naltrexone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone with nicotine patch
Study: 14629244
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A injections (25 units into each corrugator supercilii muscle, total 50 units)
Study: 20736816
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A injections
Study: 8665991
Drug: FER 5
Normalized name: Sur-Fit Wafer 57mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: FER 5 mg 9 mm tablets
Study: 8665991
Drug: FER 5
Normalized name: Sur-Fit Wafer 57mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: FER 5 mg 11 mm tablets
Study: 351351
Drug: Influenza subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza subunit vaccine
Study: 12222085
Drug: Various psychopharmacologic
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various psychopharmacologic treatments (specific agents not mentioned)
Study: 12222085
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies (specific agents not mentioned)
Study: 12222085
Drug: Novel agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel agents (specific agents not mentioned)
Study: 15590252
Drug: Remifentanil 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.02 mg
Study: 20306569
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg kg(‐1) midazolam orally (group M)
Study: 20306569
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg kg(‐1) midazolam orally with parental presence (group MP)
Study: 15813848
Drug: Epoetin-β 150
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin-β 150 IU/kg three times weekly for 16 weeks
Study: 11034875
Drug: Stopping valproate
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stopping valproate administration
Study: 8674327
Drug: Norepinephrine (pressor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (pressor doses)
Study: 18642046
Drug: Stapled transanal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stapled transanal rectal resection
Study: 21762279
Drug: No neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No neoadjuvant therapy and no enteral feeding products before surgery (Group 3, n=13)
Study: 20472263
Drug: Silodosin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin (4 mg twice daily)
Study: 7774212
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (DO2 > or = 600 mL/min/m2)
Study: 9635648
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (DO2 450 to 550 mL/min/m2)
Study: 28384627
Drug: Simultaneous group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous group (27 patients) received oral and intratympanic steroid injections for 2 weeks.
Study: 28384627
Drug: Sequential group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential group (23 patients) treated with oral steroids for 2 weeks and intratympanic steroids for the subsequent 2 weeks.
Study: 31259
Drug: Nonselective beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonselective beta-blockers
Study: 15728228
Drug: Docetaxel/gemcitabine (DG):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel/gemcitabine (DG): gemcitabine 1,000 mg/m(2) [days 1 and 8] plus docetaxel 100 mg/m(2) [day 8]
Study: 15728228
Drug: Vinorelbine/cisplatin (VC):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine/cisplatin (VC): vinorelbine 30 mg/m(2) [days 1 and 8] plus cisplatin 80 mg/m(2) [day 8]
Study: 8821071
Drug: Nootropic drugs
Normalized name: Other psychostimulants and nootropics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nootropic drugs
Study: 8821071
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (nootropics)
Study: 8821071
Drug: High L-dopa
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High L-dopa dosage
Study: 8821071
Drug: Nootropic drugs
Normalized name: Other psychostimulants and nootropics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nootropic drugs (responders)
Study: 8821071
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (non-responders)
Study: 8821071
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (responders)
Study: 8821071
Drug: Nootropic drugs
Normalized name: Other psychostimulants and nootropics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nootropic drugs (non-responders)
Study: 2166455
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of inhaled terbutaline (LDT), 500 micrograms four times a day
Study: 2166455
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of inhaled terbutaline (HDT), 2,000 micrograms four times a day
Study: 7219673
Drug: Dopamine (DA)
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine (DA) infusion (5 microgram/kg/min for 120 min)
Study: 7219673
Drug: L-dopa (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (500 mg p.o.)
Study: 7219673
Drug: L-dopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (100 mg p.o.) plus carbidopa (35 mg p.o.) after pretreatment with carbidopa (50 mg p.o. every 6 h for 1 day)
Study: 7219673
Drug: Nomifensine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomifensine (200 mg p.o.)
Study: 17599307
Drug: G-CSF (granulocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (granulocyte colony-stimulating factor), 263 mu g per day administered intravenously
Study: 17599307
Drug: G-CSF (granulocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (granulocyte colony-stimulating factor)
Study: 3051432
Drug: Weekly seminars
Normalized name: Semintra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly seminars with a cardiologist
Study: 596499
Drug: Physicians (pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physicians (pill users)
Study: 596499
Drug: Nurses (pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurses (pill users)
Study: 30461089
Drug: Sufficient maternal
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufficient maternal vitamin D status (25Hydroxyvitamin D ≥ 30 ng/mL) during early and late pregnancy
Study: 29143400
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intranasal naloxone
Study: 29143400
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intranasal naloxone
Study: 29143400
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intranasal naloxone
Study: 29143400
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg intramuscular naloxone (reference)
Study: 29143400
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg intravenous naloxone
Study: 29143400
Drug: Intranasal naloxone
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal naloxone (1 mg, 2 mg, 4 mg)
Study: 27145977
Drug: Intramuscular naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular naloxone (0.4 mg)
Study: 29143400
Drug: Simulation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulation of repeat dosing (2 x 2 mg i.n. vs 5 x 0.4 mg i.m.)
Study: 23101743
Drug: Antipsychotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication plus parent training (COMB)
Study: 23101743
Drug: Antipsychotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication alone (MED)
Study: 19640231
Drug: Analgesia injection
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesia injection
Study: 11884252
Drug: SonoVue (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue (0.5, 1, 2, and 4 ml)
Study: 11884252
Drug: SonoVue (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue (cumulative 7.5 ml dose)
Study: 11884252
Drug: SonoVue (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue (2.0 ml dose)
Study: 11884252
Drug: Albunex (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albunex (two injections)
Study: 1964620
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg four times daily)
Study: 7788518
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release theophylline (maximum daily dose 13 mg/kg)
Study: 2086794
Drug: Interrupted transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interrupted transdermal technique
Study: 30964423
Drug: sICM (7.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: sICM (7.2 g iodine) at 100 kVp
Study: 30964423
Drug: rICM (5.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rICM (5.4 g iodine) at 100 kVp
Study: 19858762
Drug: MDD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDD treatment (specific treatments not detailed, included pharmacological and cognitive-behavioral therapy)
Study: 19858762
Drug: Specific treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific treatments (pharmacological or cognitive-behavioral therapy)
Study: 17354027
Drug: Intravenous phospholipid
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous phospholipid (PL) infusion (200 mg/kg) weekly for 8 weeks
Study: 17354027
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo infusion
Study: 15466720
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (for lateral pillar B and B/C border groups)
Study: 15466720
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (for lateral pillar B and B/C border groups)
Study: 15466720
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (for lateral pillar group C)
Study: 15466720
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (for lateral pillar group C)
Study: 12102158
Drug: Longer delays
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer delays in diagnosis and treatment
Study: 12102158
Drug: Shorter waiting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter waiting times in diagnosis and treatment
Study: 10682561
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nylestriol
Study: 1082365
Drug: Schedule 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule 1: single intravenous push of cytosine arabinoside followed by oral methotrexate and intravenous vincristine, cycle repeated every 7 days.
Study: 1082365
Drug: Schedule 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule 2: three daily injections of cytosine arabinoside followed by vincristine and methotrexate, cycle repeated every 10 days.
Study: 30551218
Drug: Antidepressant users
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant users
Study: 30551218
Drug: No use
Approvals — FDA: no, EMA: no, PMDA: no
Description: No use of antidepressants before IBD onset
Study: 30060719
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine (8 mL injected)
Study: 30060719
Drug: Oral pain
Normalized name: Oral Pain Relief
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pain medication alone (Control)
Study: 24730361
Drug: 0.5 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL/kg of 24% sucrose with a pacifier
Study: 24730361
Drug: 0.5 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL/kg of sterile water with a pacifier
Study: 20585813
Drug: Intravenous DEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous DEX 0.3 μg kg⁻¹
Study: 17507354
Drug: Death or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Death or appropriate ICD therapy
Study: 9809861
Drug: Hydroxyzine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine (12.5 mg morning and mid-day, 25 mg evening)
Study: 9809861
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three capsules/day)
Study: 9809861
Drug: Buspirone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (5 mg morning and mid-day, 10 mg evening)
Study: 2711309
Drug: Phenytoin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (15 mg/kg) administered intravenously shortly before surgery completion and 5‐6 mg/kg/day in three divided doses for the first 3 postoperative days.
Study: 2711309
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered under identical conditions to the control group of 185 patients.
Study: 4002788
Drug: muzolimine 30
Normalized name: Muzolimine
DrugBank: Muzolimine (DB13801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: muzolimine 30 mg
Study: 598405
Drug: furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: furosemide 40 mg
Study: 31377052
Drug: Alirocumab 75/150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75/150 mg Q2W
Study: 12609561
Drug: CR BNO
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR BNO 1055 (daily dose corresponding to 40 mg herbal drug)
Study: 12609561
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (0.6 mg)
Study: 7911271
Drug: Immediate-release nisoldipine
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release nisoldipine (20 mg twice daily)
Study: 2821477
Drug: Experimental rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental rotavirus vaccine
Study: 12564024
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug treatment
Study: 29436142
Drug: AXOS (9.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXOS (9.4 g)
Study: 29436142
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 g maltodextrin + 1 g unlabelled lactose ureide)
Study: 18712409
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition supplemented with alanyl-glutamine dipeptide (Gln)
Study: 18712409
Drug: Regular parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular parenteral nutrition (Control)
Study: 1980542
Drug: Neuroleptic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic treatment under open conditions
Study: 1980542
Drug: Neuroleptic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic treatment under double-blind conditions